Kirom Bukhoroi

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. -KRBP

Retrieved on: 
Tuesday, September 6, 2022

On July 2, 2021, Kiromic closed a public offering of 8 million shares of common stock priced at $5.00 per share, conducted pursuant to a registration statement filed with the U.S. Securities and Exchange Commission on June 25, 2021 (the “Offering”).  On August 13, 2021, the Company issued a press release which made passing reference to “clinical hold issues” affecting the Company’s Investigational New Drug applications for two immunotherapy products but did not otherwise expand on what those issues were.  The press release stated, in relevant part, under the heading Events occurring after June 30, 2021 until August 13, 2021:  “Communications with the FDA -- Supported by IQVIA, instead of simply addressing the FDA’s questions with a written response only (WRO), we took the decision to apply for a Type A meeting with the FDA.  The Type A meeting will address the clinical hold issues and will allow us to discuss path toward our first-in-human dosing.” 

Key Points: 
  • NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma Inc. (Kiromic or the Company) (NASDAQ: KRBP).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Kiromic and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

ROSEN, A TOP RANKED LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

Retrieved on: 
Sunday, September 4, 2022

WHAT TO DO NEXT: To join the Kiromic BioPharma class action, go to https://rosenlegal.com/submit-form/?case_id=8051 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kiromic BioPharma class action, go to https://rosenlegal.com/submit-form/?case_id=8051 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

KRBP EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit filed against Kiromic BioPharma, Inc.

Retrieved on: 
Saturday, September 3, 2022

The action charges Kiromic with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the companys business, operations, and prospects.

Key Points: 
  • The action charges Kiromic with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the companys business, operations, and prospects.
  • Kessler Topaz Meltzer & Check, LLP encourages Kiromic investors who have suffered significant losses to contact the firm directly to acquire more information.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Weber, Coinbase, Carvana, and Kiromic and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, September 1, 2022

On July 25, 2022, before the market opened, Weber announced its preliminary third quarter 2022 financial results, including net sales between $525 million and $530 million.

Key Points: 
  • On July 25, 2022, before the market opened, Weber announced its preliminary third quarter 2022 financial results, including net sales between $525 million and $530 million.
  • The Company expected to report a net loss, noting that [p]rofitability was negatively impacted by several factors, including promotional activity to enhance retail sell through.
  • Additionally, Weber announced that Chris Scherzinger is departing from his roles as Chief Executive Officer and director of the Company.
  • For more information on the Kiromic class action go to: https://bespc.com/cases/KRBP
    About Bragar Eagel & Squire, P.C.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. - KRBP

Retrieved on: 
Tuesday, August 30, 2022

On July 2, 2021, Kiromic closed a public offering of 8 million shares of common stock priced at $5.00 per share, conducted pursuant to a registration statement filed with the U.S. Securities and Exchange Commission on June 25, 2021 (the “Offering”).  On August 13, 2021, the Company issued a press release which made passing reference to “clinical hold issues” affecting the Company’s Investigational New Drug applications for two immunotherapy products but did not otherwise expand on what those issues were.  The press release stated, in relevant part, under the heading Events occurring after June 30, 2021 until August 13, 2021:  “Communications with the FDA -- Supported by IQVIA, instead of simply addressing the FDA’s questions with a written response only (WRO), we took the decision to apply for a Type A meeting with the FDA.  The Type A meeting will address the clinical hold issues and will allow us to discuss path toward our first-in-human dosing.” 

Key Points: 
  • NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma Inc. (Kiromic or the Company) (NASDAQ: KRBP).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Kiromic and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

KRBP CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed

Retrieved on: 
Monday, August 29, 2022

On July 16, 2021, two weeks after the closing of the ordering, Kiromic disclosed that it had received comments from the FDA on its two IND applications.

Key Points: 
  • On July 16, 2021, two weeks after the closing of the ordering, Kiromic disclosed that it had received comments from the FDA on its two IND applications.
  • Were focused on investors losses and proving Kiromic misled investors by failing to disclose the June FDA clinical hold communications, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Kiromic and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

ROSEN, A TOP RANKED FIRM, Encourages Kiromic BioPharma, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

Retrieved on: 
Monday, August 29, 2022

WHAT TO DO NEXT: To join the Kiromic BioPharma class action, go to https://rosenlegal.com/submit-form/?case_id=8051 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kiromic BioPharma class action, go to https://rosenlegal.com/submit-form/?case_id=8051 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kiromic, Tuya, LifeStance, and MINISO and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, August 27, 2022

The Offering Documents failed to disclose this information, instead representing that clinical testing was expected to proceed in the third quarter of 2021.

Key Points: 
  • The Offering Documents failed to disclose this information, instead representing that clinical testing was expected to proceed in the third quarter of 2021.
  • Clinical testing did not proceed in the third quarter of 2021, nor was it likely given the FDAs imposition of a clinical hold.
  • For more information on the MINISO class action go to: https://bespc.com/cases/MNSO
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Gainey McKenna & Egleston Filed A Class Action Lawsuit Against Kiromic BioPharma, Inc. (KRBP)

Retrieved on: 
Saturday, August 27, 2022

NEW YORK, Aug. 26, 2022 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston is the only firm that filed a class action lawsuit against Kiromic BioPharma, Inc. (Kiromic or the Company) (NASDAQ: KRBP) and against certain officers and directors of the Company regarding the allegations below.

Key Points: 
  • NEW YORK, Aug. 26, 2022 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston is the only firm that filed a class action lawsuit against Kiromic BioPharma, Inc. (Kiromic or the Company) (NASDAQ: KRBP) and against certain officers and directors of the Company regarding the allegations below.
  • Plaintiff pursues claims against Defendants under the Securities Act of 1933 and the Securities Exchange Act of 1934.
  • If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Kiromic BioPharma, Inc. of Securities Class Action Lawsuit and Urges Investors with Significant Losses to Contact the Firm

Retrieved on: 
Friday, August 26, 2022

As a result of Kiromics materially misleading statements and omissions to the public, Kiromic investors have suffered significant losses.

Key Points: 
  • As a result of Kiromics materially misleading statements and omissions to the public, Kiromic investors have suffered significant losses.
  • We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.
  • Kessler Topaz Meltzer & Check, LLP encourages Kiromic investors who have suffered significant losses to contact the firm directly to acquire more information.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.